Ann: PTX-200 High Overall Response in Ph2a Breast Cancer trial, page-304

:Hi psych101

Absolutely will provide to you once I get it (I have asked the company for the stat in the first instance).

Given the average (beware of averages though!) is at 22 months in December that is an extremely impressive ORR. If they are saying most relapse in first 2 years, and 60% within 5 years, it would be safe to assume a 30% relapse within 2 years. If the ORR of 100% after all of the participants reach the 2 year mark (will not know for quite a while), then that is unbelievable. I really hope that they can maintain a high ORR, as what a great outcome for patients.

I must be missing something as this company seems to be out of favour with the market, and its results, and their diversified pipeline of products seem good from my limited analysis. Maybe it is the study size, but it is expensive and difficult to have large study sizes while you are proving it up, I think they will hold that for Phase 3 and with a partner. This company also seems to be well run.